Credo Technology Group Holding Ltd vs Medtronic PLC — how do they compare? Credo Technology Group Holding Ltd trades at $222.92 (market cap $44.04B), while Medtronic PLC trades at $81.44 (market cap $101.51B). The key difference: Medtronic PLC is far larger — about 2.3× Credo Technology Group Holding Ltd's market cap, and Medtronic PLC pays a 3.63% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals.
| CRDO | MDT | |
|---|---|---|
Market Cap | $44.04B | $101.51B |
Sector | Technology | Health |
52-Week High | $302.52 | $105.35 |
52-Week Low | $87.81 | $73.75 |
Enterprise Value | $42.62B | $120.25B |
Dividend Yield | — | 3.63% |
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $236.88, down 8.11% over the past 24 hours, with technical indicators showing neutral momentum near key support at $231. The company demonstrates exceptional fundamental strength with 35.37% net income margin and 34.41% ROE, though valuation metrics appear elevated with a P/E of 94.1. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.16 surpassing the $1.02 forecast.
The outlook remains positive with analyst consensus at $273.33 target (15.4% upside) and 87% buy ratings. Key risks include high valuation multiples and dependence on AI infrastructure demand growth. The company's strong cash flow generation and triple-digit revenue growth projections for 2026 support continued upside potential despite near-term volatility.
Medtronic (MDT) trades at $83.57, down 0.36% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $97.50. The company reported strong revenue growth to $33.54B in 2025, with net income of $4.66B and a net margin of 13.2%. Recent acquisitions, such as Scientia Vascular (PRNewsWire, 2026-06-12), and consistent earnings beats highlight operational strength and strategic expansion in medical technology.
MDT presents a compelling investment case with a 3.5% dividend yield and undervalued metrics relative to growth, but faces risks from rising debt levels and margin pressures. Analyst sentiment is strongly bullish with 58% buy ratings, though investors should monitor execution on fiscal 2027 guidance and macroeconomic headwinds impacting healthcare spending.
Trailing returns across standard periods
Latest headlines on both assets
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →